Results 1 to 10 of about 3,335 (217)

Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells.

PLoS ONE, 2014
The orphan receptor sigma-1 (sigmar-1) is a transmembrane chaperone protein expressed in both the central nervous system and in immune cells. It has been shown to regulate neuronal differentiation and cell survival, and mediates anti-inflammatory ...
Attila Szabo, Attila Kovacs, Ede Frecska, Eva Rajnavolgyi   +3 more
doaj   +2 more sources

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects

PCN Reports, 2023
Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It is formed from two basic components, the Banisteriopsis caapi vine and a plant containing the potent psychedelic dimethyltryptamine (DMT), usually Psychotria viridis.
Simon G. D. Ruffell, Max Crosland‐Wood, Rob Palmer, Nige Netzband, WaiFung Tsang, Brandon Weiss, Sam Gandy, Tessa Cowley‐Court, Andreas Halman, Diana McHerron, Angelina Jong, Tom Kennedy, Eleanor White, Daniel Perkins, Devin B. Terhune, Jerome Sarris   +15 more
doaj   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Effects of hallucinogenic drugs on the human heart

Frontiers in Pharmacology
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT2A-serotonin receptors in the brain.
Joachim Neumann, Stefan Dhein, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs   +4 more
doaj   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada

Addiction, Volume 121, Issue 7, Page 1781-1793, July 2026.
Abstract Background and aims Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...
Daniel T. Myran, Rachael MacDonald‐Spracklin, Alexander R. Levesque, Michael Pugliese, Jess G. Fiedorowicz, André J. McDonald, Joshua D. Rosenblat, Ian Colman, Josephine Zein, Marco Solmi   +9 more
wiley   +1 more source

The void and the brain

Cell Reports
Blackburne et al. track the electroencephalogram activity of volunteers inhaling a high dose of the powerful psychedelic 5-methoxy-N,N-dimethyltryptamine, revealing profoundly slowed-down brain activity but no significant reduction of alpha band power ...
Christof Koch
doaj   +1 more source

Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience

Scientific Reports, 2022
Understanding the phenomenology and content of the inhaled N, N, dimethyltryptamine (N, N-DMT) experience is critical to facilitate and support ongoing research and therapeutic models targeting mental health conditions and central nervous system ...
David Wyndham Lawrence, Robin Carhart-Harris, Roland Griffiths, Christopher Timmermann   +3 more
doaj   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source